MCL1 and neoplasm: Potentially, if a safe therapeutic window can be established, co-dosing of AZD0466 with an MCL-1 inhibitor could be feasible, and presents an attractive strategy, especially given that we and others, have shown that optimal tumor cell killing can be achieved with BCL-XL and MCL-1 co-inhibition33–35.